Optimizing Oncology Therapeutics Through Quantitative Translational and Clinical Pharmacology: Challenges and Opportunities
Citations Over TimeTop 1% of 2014 papers
Abstract
Despite advances in biomedical research that have deepened our understanding of cancer hallmarks, resulting in the discovery and development of targeted therapies, the success rates of oncology drug development remain low. Opportunities remain for objective dose selection informed by exposure-response understanding to optimize the benefit-risk balance of novel therapies for cancer patients. This review article discusses the principles and applications of modeling and simulation approaches across the lifecycle of development of oncology therapeutics. Illustrative examples are used to convey the value gained from integration of quantitative clinical pharmacology strategies from the preclinical-translational phase through confirmatory clinical evaluation of efficacy and safety.
Related Papers
- → Paving the Critical Path: How can Clinical Pharmacology Help Achieve the Vision?(2007)95 cited
- → Use of Healthy Volunteers Drives Clinical Oncology Drug Development Decision Making(2012)12 cited
- Phase 0 clinical trials will overcome stagnation of anticancer drug development?(2011)
- → Notes of the American Society for Clinical Pharmacology and Therapeutics(1990)2 cited